



Elixir Medical Announces Activities at Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference

Sunnyvale, California.—September 17, 2009—Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals announced today that the company's stent systems will be featured in multiple sessions at the 21st annual Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2009) taking place September 21 through 25, 2009, in San Francisco.

Clinical results from the company's Novolimus™ and Myolimus™ eluting stent systems with durable and bioabsorbable polymers will be discussed in the following sessions:

“Single center, first-in-man study of the Elixir Novolimus-eluting coronary stent system with durable polymer: Twenty-four-month clinical safety and efficacy results”. Alexandre Abizaid, M.D., Ph.D. 8:00 a.m. to 10:00 a.m., Poster Session Hall D, Tuesday, Sept. 22.

“The Elixir Bioabsorbable Polymer Myolimus-Eluting Stent Program”, Lecturer: Bernhard Witzenbichler, M.D. 2:16 p.m., DES Summit, Room 104, Tuesday, Sept. 22.

“The Elixir Bioabsorbable Polymer Novolimus-Eluting Stent Program”, Lecturer: Alexandre Abizaid, M.D., Ph.D. 2:23p.m., DES Summit, Room 104, Tuesday, Sept. 22.

About Elixir Medical

Elixir Medical Corporation, a privately held company headquartered in Sunnyvale, California, develops products that combine state-of-the-art medical devices with advanced pharmaceuticals to provide innovative treatment solutions to patients worldwide. The company's next-generation drug-eluting stent systems optimize localized drug delivery to provide a safe and effective treatment for cardiovascular patients. For more information, visit www.elixirmedical.com.

Media Contact:

Donna Collins

+1.408.636.2029

###